Research map: The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial · 2026 · Related
  3. Cholangiocarcinoma 2020: the next horizon in mechanisms and management · Jesús M. Bañales · 2020 · 2542 citations · Cited by this paper
  4. Early-onset biliary tract cancers: clinical and molecular insights · 2026 · Related
  5. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study · Ghassan K. Abou‐Alfa · 2020 · 1640 citations · Cited by this paper
  6. Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer · 2026 · Related
  7. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study · Ghassan K. Abou‐Alfa · 2020 · 1122 citations · Cited by this paper
  8. A prospective, multicenter, observational study of trastuzumab deruxtecan in elderly patients with HER2-positive gastric cancer: EN-COURAGE · 2026 · Related
  9. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  10. Effectiveness of FTD/TPI plus bevacizumab and impact of prior bevacizumab exposure in patients with mCRC: the Italian FLOWER study · 2026 · Related
  11. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial · Ángela Lamarca · 2021 · 787 citations · Cited by this paper
  12. Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort study · 2026 · Related
  13. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Arndt Vogel · 2022 · 719 citations · Cited by this paper
  14. Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer · 2026 · Related
  15. Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma · Lipika Goyal · 2023 · 608 citations · Cited by this paper
  16. BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer · 2026 · Related
  17. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation · Andrew Xiuxuan Zhu · 2021 · 513 citations · Cited by this paper
  18. Incidence, treatment variation, and survival of synchronous head and neck and esophageal carcinomas: a descriptive nationwide cohort study in the Netherlands · 2026 · Related
  19. Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications · Chaitanya R. Churi · 2014 · 461 citations · Cited by this paper
  20. Recent advances in loco-ablative therapies for liver cancers · 2026 · Related
  21. Biliary cancer: Utility of next‐generation sequencing for clinical management · Milind M. Javle · 2016 · 419 citations · Cited by this paper
  22. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas · Pu Wang · 2012 · 399 citations · Cited by this paper
  23. Impact of Classification of Hilar Cholangiocarcinomas (Klatskin Tumors) on the Incidence of Intra- and Extrahepatic Cholangiocarcinoma in the United States · Tania Mara Welzel · 2006 · 373 citations · Cited by this paper
  24. Clinicogenomic Analysis of FGFR2 -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib · Ian M. Silverman · 2020 · 299 citations · Cited by this paper
  25. Cancer and liver cirrhosis: implications on prognosis and management · Matthias Pinter · 2016 · 298 citations · Cited by this paper
  26. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study · James J. Harding · 2023 · 285 citations · Cited by this paper
  27. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review · Audra N. Boscoe · 2019 · 212 citations · Cited by this paper
  28. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma · Gajanan Kendre · 2022 · 176 citations · Cited by this paper
  29. Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets · Andrew Xiuxuan Zhu · 2014 · 149 citations · Cited by this paper
  30. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) · Choong‐kun Lee · 2022 · 130 citations · Cited by this paper
  31. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer · Arndt Vogel · 2024 · 110 citations · Cited by this paper
  32. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients · Andrea Ruzzenente · 2015 · 101 citations · Cited by this paper
  33. An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 · Arndt Vogel · 2024 · 100 citations · Cited by this paper
  34. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial · Arndt Vogel · 2024 · 54 citations · Cited by this paper
  35. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology · Al B. Benson · 2025 · 54 citations · Cited by this paper
  36. IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment—Current State and Future Perspectives · Fabiana Crispo · 2020 · 31 citations · Cited by this paper
  37. Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience · Margherita Rimini · 2023 · 21 citations · Cited by this paper
  38. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients · Margherita Rimini · 2023 · 13 citations · Cited by this paper
  39. Cirrhosis in intrahepatic cholangiocarcinoma: prognostic importance and impact on survival · Nimish Thakral · 2023 · 12 citations · Cited by this paper

Source: OpenAlex (CC0)